Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Garmin Ltd. (GRMN) vs Zoetis Inc (ZTS) Price & Performance

Garmin Ltd.Trade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Garmin Ltd. vs Zoetis Inc — how do they compare? Garmin Ltd. trades at $268.18 (market cap $51.77B), while Zoetis Inc trades at $74.39 (market cap $30.20B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Zoetis Inc for 70 Days on average.

GRMNZTS
Market Cap
$51.77B$30.20B
Volume
961,3986,175,327
Sector
TechnologyHealth
52-Week High
$313.16$147.53
52-Week Low
$187.10$69.09
Typical Hold Time
83 Days70 Days
Enterprise Value
$49.28B$37.76B
Dividend Yield
1.56%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Garmin Ltd.

Garmin (GRMN) trades at $268.51, down 2.77% today, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income show steady growth, reaching $7.25B and $1.66B in 2025, respectively, supported by strong profitability margins. Recent news highlights product innovations and industry awards, reinforcing its market position.

The outlook remains positive given earnings momentum and a consensus price target of $320.25, implying significant upside. However, high valuation ratios and bearish technical indicators pose near-term risks. Investors should weigh strong fundamentals against potential volatility and competitive pressures in the consumer electronics space.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GRMN
100% Buy0% Sell
Avg holding period · 83 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Garmin Ltd.

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Read more on GRMN →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →